Antithrombotic Therapy for Atrial Fibrillation
John J. You(Trillium Health Centre), Gregory Y.H. Lip(Medical University of Białystok), Daniel E. Singer(Massachusetts General Hospital), Alan S. Go(Kaiser Permanente), Patricia Howard(University of Kansas Medical Center), Margaret C. Fang(San Francisco General Hospital), Warren J. Manning(Beth Israel Deaconess Medical Center), Elaine M. Hylek(Boston University), Sam Schulman(Thrombosis and Atherosclerosis Research Institute), Jonathan L. Halperin(Icahn School of Medicine at Mount Sinai), Michael Hughes(Decision Research), Mark H. Eckman(University of Cincinnati), Frederick A. Spencer(McMaster University), Deirdre A. Lane(University of Liverpool)
Cited by 919
Related Papers
Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization
|New England Journal of Medicine|2004|11.4k
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Prevalence of Diagnosed Atrial Fibrillation in Adults
|JAMA|2001|6.2k
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
|Stroke|2014|5.2k
Heart Disease and Stroke Statistics—2013 Update
|Circulation|2012|5.2k